Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 794
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
J Biol Regul Homeost Agents ; 28(1): 141-5, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24750800

RESUMEN

Body weight is controlled by our genes and managed by a neuro-hormonal system, in particular by insulin and glucagon. The meristematic extract of Japanese white mulberry blocks the alpha-glucosidase and then the intestinal hydrolysis of polysaccharides, thereby reducing the glycaemic index of carbohydrates. The target of our research was to evaluate the adjuvant slimming effect of the extract of white Japanese mulberry in the dietetic treatment of some patients who are obese or overweight. 46 overweight people were enrolled and divided into two subgroups: the subjects of both subgroups were given an identical balanced diet of 1300 kcal: subjects of the subgroup alpha received 2400 mg of white Japanese mulberry extract, the subgroup b subjects receive placebo. Each subgroup was followed-up every 30 days at 30, 60 and 90 days of treatment. Both in the periodic inspections and in the final inspection measurements of body weight and waist circumference in all the subjects and thigh circumference in women only were repeated. All subjects repeated blood tests. In the subgroup alpha, weight loss was about 9 kg in 3 months, equal to approximately 10 percent of the initial weight, significantly higher than subgroup beta (P<0.0001); moreover, the plasma insulin and glucose curves of the volunteers in this subgroup at the end of the trial were lower than those performed at the time of enrolment. In the 20 women of the beta subgroup treated with only low-calorie diet and with placebo, weight reduction was globally of 3.2 kg, approximately equal to 3 percent of the initial weight; moreover, the blood glucose curves and the insulin curves showed a slight decline compared to baseline, but not so significantly as was the case for group alpha. Waist circumference and thigh circumference (in women) decreased in all participants, obviously more evidently in subjects who lost more kg. The extract of white Japanese mulberry may represent a reliable adjuvant therapy in the dietetic treatment of some patients who are obese or overweight.


Asunto(s)
Suplementos Dietéticos , Morus , Obesidad/tratamiento farmacológico , Extractos Vegetales/administración & dosificación , Adulto , Glucemia/análisis , Femenino , Humanos , Insulina/sangre , Masculino , Persona de Mediana Edad , Circunferencia de la Cintura , Pérdida de Peso
2.
Int J Immunopathol Pharmacol ; 25(3): 751-5, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23058025

RESUMEN

Several clinical forms of mucormycosis are recognized. The tendency of mucoraceous zygomycetes to invade the blood vessels often produces a disseminated infection. A case of disseminate mucormycosis complicated by a haemophagocytic syndrome (HS) in a 32-year-old Caucasian male is reported in this article. Few cases of infection-associated HS (IAHS), involving infections caused by fungi, have been reported. In all the recorded cases, the fungal infection coexists with malignant lymphoma, immunodeficiency and a long-term steroid therapy for renal transplant or Crohn's disease. This is the second described case of the HS due to mucormycosis.


Asunto(s)
Linfohistiocitosis Hemofagocítica/microbiología , Mucormicosis/microbiología , Adulto , Autopsia , Biopsia , Examen de la Médula Ósea , Resultado Fatal , Mucosa Gástrica/patología , Humanos , Inmunosupresores/uso terapéutico , Hígado/patología , Linfohistiocitosis Hemofagocítica/diagnóstico , Linfohistiocitosis Hemofagocítica/tratamiento farmacológico , Masculino , Mucormicosis/complicaciones , Mucormicosis/diagnóstico , Mucormicosis/tratamiento farmacológico , Valor Predictivo de las Pruebas , Resultado del Tratamiento
3.
Minerva Med ; 103(2): 123-40, 2012 Apr.
Artículo en Italiano | MEDLINE | ID: mdl-22513517

RESUMEN

Iron is an important metal in the complex biochemistry in human beings. However there are primary or secondary diseases that lead to an accumulation of iron in parenchymal organs and induce progressive and serious systemic harm. This review aims to define the fundamental steps of cell biology and physiology of iron and the pathophysiological mechanisms responsible for its accumulation in the parenchyma. In addition, we analyze the main primitive (hemochromatosis) and secondary (inflammation, liver diseases and hematological) diseases, responsible for the damage caused by iron, and we analyze the clinical consequences of iron overload. Furthermore, we pass under review a particular classification of general mechanisms and kinetics of iron overload responsible for its clinical phenotypes, dividing them into systemic, cellular and subcellular overload mechanisms. Finally we describe the main pathologic stages resulting from iron overload, with particular reference to liver damage and progression to hepatocellular carcinoma.


Asunto(s)
Sobrecarga de Hierro/etiología , Hierro/farmacocinética , Hepatopatías/etiología , Péptidos Catiónicos Antimicrobianos/biosíntesis , Péptidos Catiónicos Antimicrobianos/fisiología , Carcinoma Hepatocelular/etiología , Membrana Celular/metabolismo , Hemocromatosis/complicaciones , Hemocromatosis/genética , Hemocromatosis/metabolismo , Hepcidinas , Humanos , Absorción Intestinal/fisiología , Hierro/fisiología , Sobrecarga de Hierro/diagnóstico , Sobrecarga de Hierro/metabolismo , Sobrecarga de Hierro/patología , Hígado/metabolismo , Hígado/patología , Hepatopatías/metabolismo , Hepatopatías/patología , Neoplasias Hepáticas/etiología , Transferrina/metabolismo
4.
Eur Rev Med Pharmacol Sci ; 15(6): 637-43, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21796867

RESUMEN

BACKGROUND: Irritable bowel syndrome (IBS) is a very common functional gastrointestinal (GI). Diagnosis of IBS is based on the fulfilment of the Rome III criteria. Common GI symptoms are lower abdominal pain, bloating and disturbed defecation, such as urgent diarrhoea and/or episodes of chronic constipation. Many agents have been employed in the management of IBS, although only few have been demonstrated to show a relevant efficacy. AIM: To evaluate the effectiveness of the administration of a mixture of beta-glucan, inositol and digestive enzymes (Biointo) in improving GI symptoms in patients affected by IBS. PATIENTS AND METHODS: 50 IBS patients (20 males, 30 females; mean age 51 +/- 19) were treated with Biointo (group A) while another group consisting of 40 IBS patients (15 males, 25 females; mean age 50 +/- 18) did not receive any therapy (group B). RESULTS: Biointol administration improved significantly bloating, flatulence and abdominal pain, with a slight increasing of urgency for bowel movements. On the contrary, Biointol did not show any significant effect on the other IBS symptoms. CONCLUSIONS: Currently, only few agents used in the management of IBS have been proven to be effective. Biointol administration has shown to improve some IBS symptoms, such as bloating, flatulence and abdominal pain, all connected to the presence of gas inside the intestinal lumen.


Asunto(s)
Terapia Enzimática , Inositol/uso terapéutico , Síndrome del Colon Irritable/tratamiento farmacológico , beta-Glucanos/uso terapéutico , Dolor Abdominal/tratamiento farmacológico , Dolor Abdominal/etiología , Adulto , Anciano , Combinación de Medicamentos , Enzimas/administración & dosificación , Femenino , Flatulencia/tratamiento farmacológico , Flatulencia/etiología , Fármacos Gastrointestinales/administración & dosificación , Fármacos Gastrointestinales/uso terapéutico , Humanos , Inositol/administración & dosificación , Síndrome del Colon Irritable/fisiopatología , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , beta-Glucanos/administración & dosificación
5.
Minerva Med ; 102(2): 133-9, 2011 Apr.
Artículo en Italiano | MEDLINE | ID: mdl-21483400

RESUMEN

AIM: Management of functional dyspepsia is still controversial. Different controlled trials reported a superiority of prokinetics, H2-receptor antagonists and proton-pump inhibitors over placebo; nevertheless, symptomatic improvement after therapy is often incomplete and some of these drugs possess serious side effects. The aim of the study was to evaluate the efficacy of a new medical device in respect to domperidone in patients with functional dyspepsia. METHODS: In a cross-over, randomized trial, 36 patients with functional dyspepsia ingested two daily doses of a medical device (Digerfast) or domperidone (Peridon) for 21 days. Clinical evaluation was performed at baseline (T0) and after 21 days (T1) for each treatment. A Visual Analogue Scale (VAS) and the generic scale 36-item Short Form (SF-36) were used to assess symptom intensity and changes in health-related quality of life, respectively. RESULTS: At T0 no statistical difference was found for each symptom between medical device and domperidone. At T1 both treatments significantly improved in respect to baseline values all the evaluated gastrointestinal symptoms (P<0.5 for all comparisons) except for vomiting. No difference in gastrointestinal symptoms between the two treatments was found at T1. Regarding SF-36 evaluation, at T0 no statistical differences were found for each SF-36 parameter between the two regimens. At T1 both treatments significantly improved most of the evaluated SF-36 parameters in respect to baseline values. No difference in SF-36 parameters between the two treatments was found at T1. CONCLUSION: Both the medical device and domperidone significantly improved gastrointestinal symptoms and quality of life in subjects with functional dyspepsia, not showing significant difference in efficacy.


Asunto(s)
Domperidona/uso terapéutico , Dispepsia/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Citrato de Potasio/uso terapéutico , Simeticona/uso terapéutico , Sorbitol/uso terapéutico , Adulto , Estudios Cruzados , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/química , Combinación de Medicamentos , Femenino , Humanos , Masculino , Dimensión del Dolor , Calidad de Vida , Estadísticas no Paramétricas , Resultado del Tratamiento
6.
Minerva Gastroenterol Dietol ; 57(4): 369-77, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22105725

RESUMEN

H. pylori is a gram-negative pathogen, etiologically associated with atrophic and non-atrophic gastritis, peptic ulcer, primary gastric B-cell lymphoma and gastric carcinoma. Several observations demonstrated a correlation between H. pylori and malabsorption of essential nutrients; epidemiological studies have shown an association between H. pylori infection and iron deficiency anemia, while the absorption of some vitamins such as vitamin B12, vitamin A, vitamin C, folic acid and Vitamin E may be affected by the infection. The main mechanism related to malabsorption of this components is the modified intragastric pH (hypo- achlorhydria) due to H. pylori infection. Moreover H. pylori is also able to determine a modification of gastrointestinal hormones by reducing plasma levels of ghrelin and increasing those of leptin and gastrin, thus affecting appetite and promoting the occurrence of dyspeptic symptoms. On the other hand, H. pylori eradication has been shown to improve serum level of iron and vitamin B12, has some effects on Vitamin A and Vitamin E absorption and has a late effects on ghrelin levels. As a consequence of those effects, H. pylori is also associated with childhood malnutrition in developing countries either for the occurrence of malabsorption or for an increased susceptibility to enteric infections caused by hypochlorhydria.


Asunto(s)
Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Trastornos Nutricionales/etiología , Hormonas Gastrointestinales/fisiología , Humanos , Micronutrientes/fisiología
7.
Eur Rev Med Pharmacol Sci ; 25(12): 4400-4404, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-34227075

RESUMEN

OBJECTIVE: Celiac disease (CD) is an autoimmune disorder, characterized by increased susceptibility to bacterial and viral infections. Therefore, the CD patients could be exposed to an increased risk of contracting SARS-CoV-2, a virus for which the WHO declared a pandemic status in March 2020. This study aims to investigate the incidence of SARS-CoV-2 infection in CD patients, to assess the impact of CD on the risk of contracting this virus. PATIENTS AND METHODS: This retrospective multicentric cohort study evaluated 542 celiac patients, who answered a questionnaire concerning both the underlying disease (adherence to the gluten-free diet, residual symptoms) and the possible SARS-CoV-2 infection (swab outcome, presence and characteristics of symptoms and type of treatment received), referring to the period between 20th January 2020 and 27th October 2020. RESULTS: Five patients (0.92%) tested positive; of these, 2 were asymptomatic and 3 developed symptoms of COVID-19. The incidence of SARS-CoV-2 infection in CD patients was not significantly different from the general population. The ratio of positive/diagnostic swabs tends to be higher in CD patients than in the general population (IR: 0.15; 0.06; p=0.06), whereas the number of subjects who performed the swab in this group is significantly lower (IR: 0.06; 0.15; p<0.001). CONCLUSIONS: Although CD patients are more susceptible to infections, the incidence of SARS-CoV-2 infection in our sample was not significantly different from the general population. However, the positive/diagnostic swabs ratio seems to be higher, probably also due to the lower number of patients tested.


Asunto(s)
COVID-19/diagnóstico , COVID-19/epidemiología , Enfermedad Celíaca/diagnóstico , Enfermedad Celíaca/epidemiología , COVID-19/terapia , Prueba de COVID-19/métodos , Enfermedad Celíaca/terapia , Estudios de Cohortes , Dieta Sin Gluten/métodos , Humanos , Italia/epidemiología , Estudios Retrospectivos
8.
Int J Immunopathol Pharmacol ; 23(4): 1271-4, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-21244778

RESUMEN

Giant-cell arteritis (GCA) is a chronic vasculitis of the elderly usually involving the ophthalmic arteries, which can result in visual loss. High platelet counts may have some pathogenic significance in the obstruction of the ophthalmic circulation and a few cases of associated essential thrombocythaemia and GCA have been described. Here we report a case of severe temporal arteritis associated with essential thrombocythaemia.


Asunto(s)
Arteritis de Células Gigantes/etiología , Trombocitemia Esencial/complicaciones , Anciano , Anciano de 80 o más Años , Ceguera/etiología , Humanos , Masculino
9.
J Biol Regul Homeost Agents ; 24(1): 93-8, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20385075

RESUMEN

"Functional dyspepsia" represents a clinical condition of pain and/or persistent or recurrent discomfort that concerns a large portion of the healthy population. It has already been shown that some herbs (Melissa Officinalis, Cynara scolymus) can have favorable effects on digestion. The principal aim of this study is to determine whether the ingestion of "Gran Soleil" dessert, with or without herbs, after meals can be beneficial to health in subjects suffering from functional dyspepsia. For this purpose, thirty subjects with functional dyspepsia were enrolled and were asked to consume "Gran Soleil" with or without herbs; these subjects reported the course of their symptoms on VAS scale, during the basal period and after the ingestion "Gran Soleil" with and without herbs. It has been shown that the ingestion of "Gran Soleil" without herbs can induce a reduction both in the number of events connected to a dyspeptic syndrome and in their intensity; moreover the assumption of "Gran Soleil" with the addition of herbs helped to intensify this effect.


Asunto(s)
Dispepsia/dietoterapia , Dispepsia/tratamiento farmacológico , Fitoterapia , Plantas Medicinales , Frío , Cynara scolymus , Sistema Digestivo/efectos de los fármacos , Sistema Digestivo/fisiopatología , Dispepsia/fisiopatología , Femenino , Humanos , Masculino , Melissa
10.
Eur Rev Med Pharmacol Sci ; 14(4): 320-6, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20496542

RESUMEN

Although small bowel nonendocrine neoplasms are rare, their incidence has increased dramatically over the past 30 years. Small bowel malignacies can be classified depending upon their cellular origin into four principal histotypes: carcinoid tumors, adenocarcinomas, lymphomas and mesenchymal tumors. Until a few years ago, the treatment of small bowel tumors had remained relatively unchanged, with little progress in the development of effective adjuvant therapies and in the improvement of long-term survival over time. Recently, the growing interest in the understanding of the mechanisms underlying carcinogenesis has offered novel insights for the diagnosis and therapy of small bowel tumors. This review summarizes the state-of-the-art of small bowel nonendocrine tumors and the recent advancements in the knowledge of their molecular pathogenesis and cellular origin, with particular emphasis on stem cell research field.


Asunto(s)
Neoplasias Intestinales/tratamiento farmacológico , Intestino Delgado/patología , Adenocarcinoma/patología , Tumores del Estroma Gastrointestinal/patología , Humanos , Neoplasias Intestinales/genética , Neoplasias Intestinales/patología , Linfoma no Hodgkin/patología , Células Madre/patología
11.
Eur Rev Med Pharmacol Sci ; 14(3): 163-70, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20391953

RESUMEN

BACKGROUND: Lactase enzyme supplements and probiotics with high beta-galactosidase activity may be valid treatment options for the lactose intolerance. Aim of this study was to assess whether supplementation with tilactase or Lactobacillus reuteri when compared to placebo affects hydrogen breath excretion and gastrointestinal symptoms in lactose intolerant patients during lactose breath test (H,-LBT). METHODS: Sixty lactose intolerant patients participated in the study and were randomized to three 20 patients-treatment groups: tilactase group (tilactase 15 minutes before control H2-LBT); placebo group (placebo 15 minutes before control H2-LBT); Lactobacillus reuteri group (LR) (LR b.i.d. during 10 days before control H2-LBT). The outcomes were LBT normalization rate, and influences of treatments on both mean maximum hydrogen concentration and clinical score. RESULTS: LBT normalization rate was significantly higher in tilactase and LR groups with respect to placebo. Tilactase was significantly more effective than LR in achieving LBT normalization (p <0.01). Both significant reduction of mean peak H2 excretion and improvement of the mean clinical score were observed in tilactase and LR groups after treatment with respect to placebo (p <0.0001). Tilactase was significantly more effective than LR in reducing both mean peak hydrogen excretion and mean clinical score. CONCLUSIONS: In lactose intolerants, tilactase strongly improves both LBT results and gastrointestinal symptoms after lactose ingestion with respect to placebo. Lactobacillus reuteri also is effective but lesser than tilactase. This probiotic may represent an interesting treatment option for lactose intolerance since its use is simple and its effect may last in the time after stopping administration.


Asunto(s)
Terapia de Reemplazo de Hormonas , Lactasa/administración & dosificación , Intolerancia a la Lactosa/terapia , Limosilactobacillus reuteri/enzimología , Probióticos/administración & dosificación , beta-Galactosidasa/metabolismo , Dolor Abdominal/enzimología , Dolor Abdominal/microbiología , Dolor Abdominal/terapia , Administración Oral , Adulto , Pruebas Respiratorias , Diarrea/enzimología , Diarrea/microbiología , Diarrea/terapia , Femenino , Flatulencia/enzimología , Flatulencia/microbiología , Flatulencia/terapia , Humanos , Lactosa/administración & dosificación , Intolerancia a la Lactosa/complicaciones , Intolerancia a la Lactosa/enzimología , Intolerancia a la Lactosa/microbiología , Masculino , Dimensión del Dolor , Estudios Prospectivos , Factores de Tiempo , Resultado del Tratamiento
12.
Eur Rev Med Pharmacol Sci ; 14(4): 356-62, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20496548

RESUMEN

BACKGROUND AND OBJECTIVES: To provide an overview on the loco-regional therapy performed by transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), either as sole, either as neoadjuvant to surgery or bridge therapy to orthotopic liver transplantation (OLT). EVIDENCE AND INFORMATION SOURCES: The current review is based on an analysis of the current literature and the caseload experience of the Authors on this topic. STATE OF THE ART: Chemoembolization combines de-arterialization of the tumor and selective delivery of chemotherapeutic agents into tumor's feeding vessels during angiography. Tumor ischemia raises the drug concentration compared to infusion alone and extends the retention of the chemotherapeutic drug. As locoregional therapy, TACE allows a complete local tumor control of 25-35% and permits an increase of survival in patients with intermediate HCC according to Barcelona-Clinic Liver Cancer (BCLC) classification. Excellent results were also achieved by combined therapies, such as with percutaneous ethanol injection or radiofrequency ablation, as neoadjuvant therapy prior to liver resection and in some circumstances as a bridging tool before liver transplantation. PERSPECTIVES: Drug eluting beads are microspheres that can be loaded with doxorubicin and induce toxic and ischemic necrosis with the same device; that allows an increase of drug selectively exposed to tumor cells and simultaneously a reduction of systemic toxicity. Tumor embolization induces a neoangiogenic reaction with a significant growth of adiacent satellites, so the association with sorafenib has a strong rationale for a combined therapy and is currently under investigation. CONCLUSIONS: Today TACE is the standard of care for treatment of intermediate hepatocellular carcinoma. To get the best performance it should be tailored according to the individual patient's condition.


Asunto(s)
Carcinoma Hepatocelular/terapia , Quimioembolización Terapéutica , Neoplasias Hepáticas/terapia , Inhibidores de la Angiogénesis/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/patología , Terapia Combinada , Humanos , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/patología
13.
Int J Immunopathol Pharmacol ; 22(1): 1-7, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19309546

RESUMEN

Until the 1960s celiac disease (CD) or sprue was considered a pediatric disease that was rarely diagnosed in adulthood. Thanks to greater awareness of the disease and the availability of improved diagnostic tools (above all, sophisticated endoscopic techniques and the development of reliable serological markers), the prevalence of CD in Western countries has been increasing steadily, and it is now recognized as a common disorder, even in adults. However, many cases of this disease still go undiagnosed, especially among the elderly and in patients with atypical clinical presentations (which are by no means uncommon). On the other hand, the frequency of unfounded diagnoses of CD is also on the rise. This reflects a tendency toward exclusively symptomatic diagnosis as well as the growing use of invalidated tests for CD (e.g., the cytotoxic test, the sublingual or subcutaneous provocation/neutralization test, etc.). As a result, public healthcare spending is being increased in several countries (Italy included) by the growing number of prescriptions for gluten-free diets. This editorial discusses the problems of under- and over-diagnosis of CD and provides an algorithm for management of suspected cases designed to minimize both problems with particular importance to morphologic aspects of small bowel (also in electron microscopy), in basal conditions or in gluten-free diets.


Asunto(s)
Enfermedad Celíaca/diagnóstico , Enfermedad Celíaca/epidemiología , Enfermedad Celíaca/patología , Humanos , Pruebas Serológicas
14.
Int J Immunopathol Pharmacol ; 22(1): 105-13, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19309557

RESUMEN

Previous published studies have identified a class of women, Normal Weight Obese women (NWO) with normal BMI and high fat content. An important role of Interleukin-15 (IL-15) has been documented in facilitating muscle proliferation and promoting fat depletion. Indeed the presence of three types of IL-15 receptor subunits in fat tissue suggests a direct effect on adipose tissue. We studied three single nucleotide polymorphisms (SNP) of IL-15R-alpha receptor gene and investigated their relationship with NWO phenotype. We considered two classes of women according to their BMI and percent fat mass (percent FAT), class 1: including 72 overweight-obese women (high BMI-high fat mass) and class 2: including 36 NWO (normal BMI, high fat mass). Three sites of Interleukin-15 receptor subunit á gene were examined, located respectively in exon4, exon5 intron-exon border and exon7. Genotyping of the identified polymorphisms was performed by restriction fragment length polymorphism. Haplotype frequency estimation was performed by using the Mendel-University of Chicago program. Odds ratio analyses were calculated by EPISTAT program. Highly significant differences were observed for exon 7- exon5 intron-exon border and exon 4-exon 7 haplotype distribution between class 1 and class 2 women. These results strongly support the hypothesis that genetic variability of the IL-15 receptor has an important role in body fat composition. Our data underscore previous findings that suggest a potential role of IL-15 cytokine in NWO syndrome.


Asunto(s)
Peso Corporal/fisiología , Subunidad alfa del Receptor de Interleucina-15/genética , Obesidad/genética , Polimorfismo de Nucleótido Simple , Adulto , Índice de Masa Corporal , Exones , Femenino , Haplotipos , Humanos , Interleucina-15/genética , Persona de Mediana Edad , Síndrome
15.
Int J Immunopathol Pharmacol ; 22(2): 521-4, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19505404

RESUMEN

Retroperitoneal fibrosis (RPF) is a disease characterized by inflammatory fibrotic processes affecting the retroperitoneal structures. Familial Mediterranean Fever (FMF) is an autosomal recessive disorder, characterized by fever and attacks of sterile serositis. Colchicine is the only suitable drug for prevention of acute episodes. We describe a case of association between RPF and FMF in a 48-year-old male, in whom therapy with colchicine, besides preventing acute episodes, allowed RPF regression. To date the association between FMF and RPF and the use of colchicine therapy alone for RPF has not been described.


Asunto(s)
Colchicina/uso terapéutico , Fiebre Mediterránea Familiar/tratamiento farmacológico , Fibrosis Retroperitoneal/tratamiento farmacológico , Fiebre Mediterránea Familiar/complicaciones , Fiebre Mediterránea Familiar/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Inducción de Remisión , Fibrosis Retroperitoneal/complicaciones , Fibrosis Retroperitoneal/diagnóstico por imagen , Tomografía Computarizada por Rayos X , Resultado del Tratamiento
16.
J Biol Regul Homeost Agents ; 23(2): 127-31, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19589295

RESUMEN

It is well-known that digestion has a pivotal role in maintaining a state of wellbeing. The influence of certain foods and some herbal drugs has been ascertained. Epidemiological data show that the Mediterranean diet, with a high consumption of fresh vegetables and fruit, mainly citrus, has a beneficial effect and plays a protective gastrointestinal role. Previously, we assessed the influence on the eventual occurrence of symptoms during digestion of an iced dessert containing a mixture of digestive plant extracts, citrus juices and liquors, showing that its ingestion does not cause significant gastrointestinal symptoms in healthy volunteers. Taking into consideration that sensory properties of food may also influence digestion, we also evaluated the palatability of the product. In order to evaluate the effect of different tastes on the digestive processes, we performed a further similar evaluation with two new flavours. The ingestion of these iced desserts at the end of the meal does not cause significant gastrointestinal symptoms. Moreover, palatability median score shows a good appreciation of the products. Therefore, the combination of digestive herbs, citrus juice and liquors in different flavours gives rise to a product with a positive mix of good palatability, favourable acceptance and herbal constituents, able to maintain a good digestive condition.


Asunto(s)
Fenómenos Fisiológicos del Sistema Digestivo/efectos de los fármacos , Aromatizantes/administración & dosificación , Adulto , Anciano , Femenino , Alimentos , Humanos , Masculino , Persona de Mediana Edad , Olfato , Gusto , Temperatura , Adulto Joven
17.
Eur Rev Med Pharmacol Sci ; 13(6): 419-23, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-20085122

RESUMEN

BACKGROUND: Gastrointestinal motility disorders are often present in diabetic patients (pts). Such motility dysfunctions have been attributed to autonomic neuropathy. Impaired intestinal motility is often associated with small-bowel bacterial overgrowth (SIBO) but only few studies evaluated the relationship between autonomic neuropathy and SIBO in diabetic pts. AIM: To compare the prevalence of SIBO between type 1 diabetic (T1D) pts with and without autonomic neuropathy. PATIENTS AND METHODS: 25 pts (13 males, 12 females; mean age 44.2+/-7) affected by type 1 diabetes with normal cardiovascular autonomic test (group A) and 25 type 1 diabetic pts with abnormal cardiovascular autonomic test (group B) were submitted to hydrogen lactulose breath test. RESULTS: 2 out of 25 (8%) showed SIBO among group A, while 11 out of 25 (44%) showed SIBO among group B (p<0.01). Interestingly, among group B, the daily insulin requirements was significantly higher in SIBO-positive pts compared to SIBO-negative: 0.66+/-0.3 vs. 0.59+/-0.1 UI/kg (p<0.05). CONCLUSIONS: Pts with autonomic neuropathy have a significantly higher prevalence of SIBO, that is also associated with a higher daily insulin requirements.


Asunto(s)
Bacterias/crecimiento & desarrollo , Diabetes Mellitus Tipo 1/complicaciones , Neuropatías Diabéticas/complicaciones , Enfermedades Intestinales/epidemiología , Intestino Delgado/microbiología , Adulto , Neuropatías Diabéticas/diagnóstico , Femenino , Humanos , Enfermedades Intestinales/complicaciones , Enfermedades Intestinales/microbiología , Masculino , Persona de Mediana Edad
18.
Eur Rev Med Pharmacol Sci ; 13 Suppl 1: 37-44, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19530510

RESUMEN

Sarcoidosis is a granulomatous disease of unknown origin, with pulmonary findings in more than 90% of patients. Extrapulmonary involvement is common and all organs can be involved (especially lymph nodes, eyes, joints, central nervous system) but it is rare to find an isolated extrapulmonary disease (less than 10% of patients). Granulomatous inflammation of the spleen and the liver is common in patients with systemic sarcoidosis, while hepatosplenic enlargement is unusual and splenic involvement rare. We report two cases of systemic sarcoidosis, that onset with splenic and hepatosplenic disease, and one case with splenic sarcoidosis without pulmonary involvement. In the first case a 53-year-old woman with mild abdominal pain underwent sonography and CT, which revealed one hypoechoic/hypodense splenic lesion. Laboratory tests were normal. In order to exclude a lymphoma, splenectomy was performed: histology revealed a sarcoid granuloma. After surgery the patient was asymptomatic and now, after two years, disease is silent. The second case is a 66-year-old woman with a recent weight loss (8 kg in two months) and alterated liver function tests (AST 61 U/l, ALT 72 U/l, Alkaline phosphatase 748 U/l, g-GT 381 U/l). Since she had a familiar history of colon cancer, abdominal US scan, abdominal CT scan and MRI were performed and showed inter-aorto-caval lymphadenopathies and discreet multiple bilobar hepatic and splenic substitutive lesions, with no signs of primary tumor. Upper and lower GI endoscopy, full gynecological workup, complete set of tumor markers, bone marrow biopsy were performed. All resulted negative for neoplasia. Small pulmonary infiltrations were observed on chest-CT scan but cytology on BAL was normal. Infections were also excluded. An exploratory laparotomy showed whitish peritoneal, hepatic and splenic nodules. The histological exam revealed chronic granulomatous lesions typical for sarcoidosis. During a two-year follow-up after the splenectomy the patient feels well without any treatment. The third patient is a 32-year-old woman with mild epigastric pain after meals. Neck-thoracic CT, bone scintigraphy and upper GI endoscopy were negative. Abdominal US and MR showed splenomegaly with multiple splenic lesions. Splenectomy was performed and histological exam showed chronic granulomatous lesions typical for sarcoidosis. Further laboratory tests were normal, except for ACE (66 UI/l). After the surgery ACE became normal and now, three years later, the patient is still asymptomatic. We conclude that hepatosplenic involvement is less rare than it is thought. It is often oligosymptomatic or accompanied with unspecific manifestations and laboratory abnormalities. The diagnosis could be difficult; in fact typical laboratory findings of sarcoidosis such as ACE, lysozyme, calcium, were not diagnostic. Ultrasonography and CT were important but the diagnosis was established only with the histological examination of suspected lesions. This latter required to differentiate liver and/or spleen sarcoidosis from tuberculosis and other infections, primary biliary cirrhosis, metastasis or malignant lymphoma.


Asunto(s)
Hepatopatías/complicaciones , Sarcoidosis/complicaciones , Enfermedades del Bazo/complicaciones , Adulto , Anciano , Femenino , Humanos , Hepatopatías/terapia , Persona de Mediana Edad , Sarcoidosis/diagnóstico , Sarcoidosis/diagnóstico por imagen , Enfermedades del Bazo/cirugía , Enfermedades del Bazo/terapia , Tomografía Computarizada por Rayos X
19.
Eur Rev Med Pharmacol Sci ; 13(2): 111-6, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19499846

RESUMEN

BACKGROUND AND OBJECTIVES: Few controlled trials on antibiotic therapy for small intestinal bacterial overgrowth are available at present. Aim of the study was to assess efficacy, safety and tolerability of rifaximin with respect to metronidazole for the treatment of small intestinal bacterial overgrowth. MATERIAL AND METHODS: We enrolled 142 consecutive patients with diagnosis of small intestinal bacterial overgrowth. Diagnosis of small intestinal bacterial overgrowth based on the clinical history and the positivity of glucose breath test. Patients were randomised to two 7-day treatment groups: rifaximin 1200 mg/day and metronidazole 750 mg/day. Glucose breath test was reassessed 1 month after. Compliance and side-effect incidence were also evaluated. RESULTS: One drop-out was observed in rifaximin group. Five drops-out occurred in metronidazole group. The glucose breath test normalization rate was significantly higher in the rifaximin with respect to the metronidazole group (63.4% versus 43.7%; p < 0.05; OR 1.50, 95% CI 1.14-4.38). The overall prevalence of adverse events was significantly lower in rifaximin with respect to metronidazole group. DISCUSSION: Rifaximin showed an higher SIBO decontamination rate than metronidazole at the tested doses, both with a significant gain in terms of tolerability. Either the present study or recent evidencies suggest that rifaximin represents a good choice for the management of patients affected by SIBO.


Asunto(s)
Antiinfecciosos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Metronidazol/uso terapéutico , Rifamicinas/uso terapéutico , Adulto , Antiinfecciosos/efectos adversos , Infecciones Bacterianas/diagnóstico , Pruebas Respiratorias/métodos , Femenino , Glucosa/análisis , Humanos , Intestino Delgado/microbiología , Masculino , Cumplimiento de la Medicación , Metronidazol/efectos adversos , Persona de Mediana Edad , Estudios Prospectivos , Rifamicinas/efectos adversos , Rifaximina , Adulto Joven
20.
Eur Rev Med Pharmacol Sci ; 13 Suppl 1: 45-50, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19530511

RESUMEN

Amyloidosis is a rare disease caused by extracellular deposits of insoluble fibrillar proteins in various organs and tissues. There are different forms of amyloidosis distinguished by the type of protein fibrils, by the sites of deposition and by associated conditions. Gastrointestinal involvement is common both in primary and secondary amyloidosis, while isolated gastrointestinal amyloidosis is rare. We describe a case of AL amyloidosis with a gastrointestinal involvement and restrictive cardiomiopathy. A 64 year old woman came to our attention with a history of chronic diarrhoea and weight loss, associated with dysphagia, dry mouth, xerophtalmia, chronic gastritis and depression. Clinical diagnosis has been difficult because of aspecificity of symptoms that mimed other more common diseases, like gastro-paresis, epigastric discomfort, gastric or duodenal ulcers, perforation, malabsorption, intestinal pseudo-obstruction. There is an important risk of misunderstanding and diagnostic delay. Indeed in this patient a diagnosis of irritable colon syndrome was erroneously established two years before admission in our hospital. Therefore gastrointestinal amyloidosis should be considered among differential diagnoses of chronic diarrhoea and weight loss when other more common diseases have been excluded.


Asunto(s)
Amiloidosis/diagnóstico , Diarrea/etiología , Enfermedades Gastrointestinales/diagnóstico , Amiloidosis/complicaciones , Amiloidosis/diagnóstico por imagen , Cardiomiopatías/diagnóstico , Cardiomiopatías/diagnóstico por imagen , Enfermedad Crónica , Diagnóstico Diferencial , Femenino , Enfermedades Gastrointestinales/complicaciones , Humanos , Persona de Mediana Edad , Ultrasonografía , Pérdida de Peso
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA